Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia

Psychopharmacology

Volumn 231, Issue 2, 2014, Pages 319-325

  Song, Xueqin ^a,b,c   Fan, Xiaoduo ^c   Li, Xue ^a   Zhang, Wei ^a   Gao, Jinsong ^a   Zhao, Jingping ^d   Harrington, Amy ^c   Ziedonis, Douglas ^c   Lv, Luxian ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Inflammation; Interleukin 1 ; Interleukin 6; Schizophrenia; Tumor necrosis factor

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; RISPERIDONE; TUMOR NECROSIS FACTOR ALPHA; NEUROLEPTIC AGENT;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIRST EPISODE SCHIZOPHRENIA; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ADOLESCENT; BLOOD; DRUG EFFECTS; MIDDLE AGED; TIME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892807356     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3382-4     Document Type: Article

References (41)

1. Amrami-Weizman A, Maayan R, Gil-Ad I, Pashinian A, Fuchs C, Kotler M, Poyurovsky M (2013) The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients. Psychopharmacology (Berlin) 230:23-27
2. Barzilay JI, Forsberg C, Heckbert SR, Cushman M, Newman AB (2006) The association of markers of inflammation with weight change in older adults: the Cardiovascular Health Study. Int J Obes (London) 30:1362-1367
3. Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL (2013) Weight change by baseline BMI from 3-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. J Psychopharmacol 27:358-365, Oxford, England
4. Chen C, Lu FC, Department of Disease Control Ministry of Health, P.R.C. (2004) The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci: BES 17:1-36
5. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Tzeng NS, Lee IH, Chen PS, Yeh TL, Huang SY, Yang YK, Lu RB, Hong JS (2012) Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J Neuroimmune Pharm 7:656-664
6. Davey KJ, O'Mahony SM, Schellekens H, O'Sullivan O, Bienenstock J, Cotter PD, Dinan TG, Cryan JF (2012) Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berlin) 221:155-169
7. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS (2006) Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 20:532-545
8. el-Mallakh RS, Suddath RL, Wyatt RJ (1993) Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 17:383-391
9. Fan X, Goff DC, Henderson DC (2007) Inflammation and schizophrenia. Expert Rev Neurother 7:789-796
10. Fan X, Borba CP, Copeland P, Hayden D, Freudenreich O, Goff DC, Henderson DC (2013) Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 127:217-226
11. Fawzi MH, Fawzi MM, Fawzi MM, Said NS (2011) C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 190:91-97
12. Fineberg AM, Ellman LM (2013) Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry 73:951-966
13. Garver DL, Tamas RL, Holcomb JA (2003) Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 28:1515-1520
14. Holz T, Thorand B, Doring A, Schneider A, Meisinger C, Koenig W (2010) Markers of inflammation and weight change in middle-aged adults: results from the prospective MONICA/KORA S3/F3 study. Obesity 18:2347-2353, Silver Spring, Md
15. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860-867
16. Jassim G, Skrede S, Vazquez MJ, Wergedal H, Vik-Mo AO, Lunder N, Dieguez C, Vidal-Puig A, Berge RK, Lopez M, Steen VM, Ferno J (2012) Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology (Berlin) 219:783-794
17. Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, Chang K (2013) Associations Among Obesity, Acute Weight Gain, and Response to Treatment with Olanzapine in Adolescent Schizophrenia. J Child Adolesc Psychopharmacol
18. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B (2009) Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 59:123-129
19. Leonard BE, Schwarz M, Myint AM (2012) The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol 26:33-41, Oxford, England
20. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH (1993) Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 150:1408-1410
21. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M (1998) The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32:9-15
22. Martinez-Gras I, Garcia-Sanchez F, Guaza C, Rodriguez-Jimenez R, Andres-Esteban E, Palomo T, Rubio G, Borrell J (2012) Altered immune function in unaffected first-degree biological relatives of schizophrenia patients. Psychiatry Res 200:1022-1025
23. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, Lieberman JA (2009) Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 66:1013-1022
24. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663-671
25. Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpe S, Steinbusch HW, Leonard BE, Kim YK (2011) Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun 25:1576-1581
26. Na KS, Kim YK (2007) Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 56:55-63
27. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM (1997) A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res 26:227-233
28. Nunes SO, Matsuo T, Kaminami MS, Watanabe MA, Reiche EM, Itano EN (2006) An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophr Res 84:180-182
29. O'Brien SM, Scully P, Dinan TG (2008) Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res 160:256-262
30. Odegaard JI, Chawla A (2013) Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 339:172-177
31. Ou JJ, Xu Y, Chen HH, Fan X, Gao K, Wang J, Guo XF, Wu RR, Zhao JP (2013) Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. Psychopharmacology (Berlin) 225:627-635
32. Pollmacher T, Hinze-Selch D, Mullington J (1996) Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 16:403-409
33. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63:801-808
34. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM (1997) CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 25:123-129
35. Ritchie SA, Connell JM (2007) The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis: NMCD 17:319-326
36. Rudolf S, Peters M, Rothermundt M, Arolt V, Kirchner H (2002) The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro. Neuropsychobiology 46:180-185
37. Runeson BS, Rich CL (1994) Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. (DSM-III), adaptive functioning in young Swedish suicides. Ann Clin Psychiatry: Off J Am Acad Clin Psychiatr 6:181-183
38. Schattner A, Cori Y, Hahn T, Sirota P (1996) No evidence for autoimmunity in schizophrenia. J Autoimmun 9:661-666
39. Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP (2009) The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 65:481-488
40. Tateya S, Kim F, Tamori Y (2013) Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne) 4:93
41. Vasunilashorn S (2013) Retrospective reports of weight change and inflammation in the US National Health and Nutrition Examination Survey. J Obes 2013:601534